Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis

Table 1 Demographic and clinical characteristics ^a

Clinical features	% ( n/ N) or mean ± SD
Patients	2,137
Main characteristics
Age at disease onset (yr)	53 ± 14.8
Follow-up duration (yr)	12.5 ± 8.25
Females (%)	75.1
Rheumatoid factor–positive^b	68.3 (1,413/2,070)
Anti-CCP antibody–positive	57.3 (1,024/1,785)
Shared epitope–positive	62.6 (734/1,173)
Erosions	54.4 (866/1,591)
Extraarticular manifestations^c	31.3 (481/1,537)
Cardiovascular risk factors
Hypertension	40.3 (846/2,100)
Diabetes mellitus	13.1 (275/2,100)
Dyslipidemia	38.3 (805/2,100)
Obesity	19.6 (413/2,100)
Smoking habit	27.4 (576/2,100)
Patients with cardiovascular events (total)	18.2 (390/2,137)
Ischemic heart disease	8.5 (181/2,137)
Heart failure	5.7 (122/2,137)
Cerebrovascular accident	5.6 (120/2,137)
Peripheral arteriopathy	2.8 (60/2,137)

^aCCP: Cyclic citrullinated peptide; SD: Standard deviation. ^bAt least two determinations were required for analysis of this result. ^cExtraarticular manifestations of disease (if RA patients had at least one of the following manifestations: nodular disease: Felty’s syndrome, pulmonary fibrosis, rheumatoid vasculitis, secondary Sjögren’s syndrome) [4].

ISSN: 1478-6362